Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Do alterations in the neural stem-cell population contribute to brain tumorigenesis? This review address how this knowledge might be used to identify new therapeutic strategies for the treatment of brain tumours, such as glioblastoma multiforme and medulloblastoma.
Gene-expression profiling and other studies have recently provided new insights into the biology of hairy-cell leukaemia (HCL). Such insights will facilitate differentiation of HCL from HCL-like disorders and lead to new targets for therapeutic intervention.
In this review the authors argue that the inhibition of cell death is an important characteristic of metastatic cancer cells. Will this view identify new treatments for metastatic disease?
p21-activated kinases (Paks) have recently been implicated in apoptosis and proliferation, as well as their established roles in cytoskeletal remodelling and motility. How do these roles contribute to tumorigenesis and are Paks a potential therapeutic target?
The recent finding that the induction of cellular senescence is associated with the premalignant stages of tumour progression indicates that markers of senescence might prove to be useful diagnostic and prognostic tools. This article presents some of the more promising candidates.
There are now many genetic tests that provide information about cancer risk. How should clinicians and policy makers ensure that the clinical uses of these tests maximize benefit and minimize harm?
